Edwards Lifesciences’ acquisition of JenaValve threatens to disrupt competition for revolutionary heart condition device, the FTC alleges
The Federal Trade Commission today moved to block medical device supplier Edwards Lifesciences Corp.’s (Edwards) proposed acquisition of JenaValve Technology, Inc. (JenaValve) due to concerns that the acquisition would limit patient access to lifesaving medical devices used to treat a potentially fatal heart condition.